Vertex Pharmaceuticals, Inc.

NASDAQ:VRTX   3:59:59 PM EDT
305.55
+11.03 (+3.74%)
Positive Earnings Pre-Announcement

Vertex Pharmaceuticals Company Raises Full Year 2022 Product Revenue Guidance To $8.6 To $8.8 Billion

Published: 08/04/2022 20:42 GMT
Vertex Pharmaceuticals, Inc. (VRTX) - Vertex Reports Second Quarter 2022 Financial Results.
Qtrly Product Revenues of $2.20 Billion, a 22% Increase Compared to Q2 2021.company Raises Full Year 2022 Product Revenue Guidance to $8.6 to $8.8 Billion.
Qtrly GAAP Net Income per Share - Diluted $3.13.
Q2 Non-GAAP Net Income per Share - Diluted $3.60.
Q2 Earnings per Share View $3.48, Revenue View $2.13 Billion -- Refinitiv Ibes Data (analyst estimates).
Q2 Earnings per Share View $3.48, Revenue View $2.13 Billion -- Refinitiv Ibes Data (analyst estimates).
FY2022 Earnings per Share View $14.10, Revenue View $8.58 Billion -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $2.22 Billion
Adjusted EPS is expected to be $3.62

Next Quarter Revenue Guidance is expected to be $2.25 Billion
Next Quarter EPS Guidance is expected to be $3.48

More details on our Analysts Page.